Semax: mechanism of action

Semax is the working name for a synthetic heptapeptide of the sequence Met-Glu-His-Phe-Pro-Gly-Pro, described in the literature as an ACTH(4-7) analogue and as a synthetic regulatory peptide [2]. It is also referred to as ACTH(4-7)PGP, and the related fragment ACTH(6-9)PGP appears alongside it in the same experimental series [5][6]. The evidence block supplies the sequence but no formula, molecular weight or registry identifier, so none is stated here. The compound is handled as a research reagent; the catalogue entry for Semax is listed for laboratory use only.

The mechanistic work centres on peptide interaction with copper ions and on peptide-driven changes in brain gene expression, with additional reports on intracellular calcium handling and on opioid-receptor-linked signalling.

Research Studies

Semax and copper stripping from Cu(II)-amyloid-beta species

An in vitro study examined whether Semax could interfere with the copper-catalysed oxidation of amyloid-beta. Semax was reported to have a high affinity for Cu(II) ions, and the results indicated that the peptide was able to extract Cu(II) from Cu(II)-amyloid-beta species and to influence the redox behaviour of the complex [2]. The authors framed this in the context of Fenton-like chemistry, in which Cu(II)/Cu(I) redox cycling of the Cu(II)-amyloid-beta complex is postulated to generate reactive oxygen species relevant to neurotoxicity in Alzheimer's disease [2]. The reported outcome was a decrease in Cu(II)-catalysed ROS production and in the cytotoxicity of amyloid-beta, attributed to metal ion stripping and redox silencing [2]. This is an in vitro finding; no animal or human data are reported in that source.

Semax and amyloidosis in a transgenic Alzheimer's model

A separate study assessed Semax and a derivative of it in a transgenic animal model of Alzheimer's disease, looking at behavioural characteristics and at the development of amyloidosis [1]. The paper situates the work against the absence of remedies that are both effective at treating or substantially slowing the pathological process and sufficiently safe, and against growing interest in natural peptide drugs [1]. The findings are animal-model findings. The evidence block does not supply effect sizes, doses or behavioural scores, so none are reported here.

Semax and gene expression in the ischaemic penumbra at 24 hours

Using RNA-Seq, researchers examined differentially expressed genes associated with ACTH(4-7)PGP (Semax) and ACTH(6-9)PGP in the penumbra-associated region of the frontal cortex of rats at 24 hours after transient middle cerebral artery occlusion [5]. The peptides were reported to significantly reduce the profile disturbances caused by ischaemia across a large set of genes [5]. The work is described as the first RNA-Seq identification of differentially expressed genes associated with these peptides in that region and at that time point [5]. All observations are in rats.

Semax and gene expression in the ischaemic frontal cortex at 4.5 hours

An earlier analysis in the same experimental line used RNA-Seq at 4.5 hours after transient middle cerebral artery occlusion in the ipsilateral frontal cortex of rat brain, again examining differentially expressed genes associated with ACTH(4-7)PGP (Semax) and ACTH(6-9)PGP under cerebral ischaemia [6]. The 24-hour study extended this by analysing the penumbra-associated frontal cortex under the same peptides [6]. Together the two reports describe a time-resolved, region-specific gene-expression response to the peptides in a rat stroke model. Both are animal studies.

Semax and intracellular calcium dynamics in rat brain neurons

A study investigated the effect of Semax on spontaneous fluctuations of intracellular calcium ion concentration in pyramidal neurons of hippocampal slices, and on the proton-induced increase in intracellular calcium in cerebellar granule cells of cerebellar slices [7]. Semax was applied at 1 micromolar in that preparation [7]. The work is an in vitro slice study in rat tissue. The evidence block does not state the direction or magnitude of the reported effects, so they are not characterised here.

Semax and Oprm1-linked deubiquitination after spinal cord injury

In female mice, Semax was reported to target the mu opioid receptor gene Oprm1, promoting deubiquitination and functional recovery after spinal cord injury [8]. The study's background links lysosomal membrane permeabilization to increased neuronal cell death after spinal cord injury, and notes that ubiquitination may affect that permeabilization by regulating the stability and functionality of lysosomal membranes [8]. Semax is described there as a synthetic heptapeptide comprising the ACTH fragment [8]. This is a rodent study in one sex; the evidence block does not provide recovery metrics.

Semax and antidepressant-like effects in a chronic stress model

Semax and Melanotan II, both described as ACTH(4-10) synthetic analogues, were examined for antidepressant-like and antistress effects in male rats in a model of chronic unpredictable stress [9]. The rationale given is that stressful events and hyperactivity of the hypothalamic-pituitary-adrenal axis play an important role in the pathogenesis of depression, and that current antidepressant therapy has substantial limitations [9]. The findings are behavioural and endocrine observations in male rats under a chronic stress protocol. No human data are reported in that source.

Semax in the wider therapeutic-peptide literature

Two review sources place Semax-type peptides within broader therapeutic-peptide fields. A narrative review of therapeutic peptides in gerontology describes the field as targeting hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline, and reports searches of PubMed, Scopus and regulatory databases from inception through January 2026 [4]. A review of therapeutic peptides in orthopaedics describes peptides as acting on pathways such as PI3K/Akt, mTOR, MAPK, TGF-beta and AMPK to influence tissue regeneration [10]. Neither review is a primary Semax study, and neither is used here to support a mechanism claim about Semax itself.

Comparison of the two ACTH-like fragments studied

The stroke-model work compared two fragments directly. The table below summarises what the evidence block states about each.

What the evidence does not establish

• No human clinical trial of Semax for any indication appears in the evidence block.
• No dose, route or exposure figure for Semax is supplied by the evidence block, and none is stated on this page.
• The copper-chelation work is in vitro [2]; the calcium work is in rat brain slices [7]; the gene-expression work is in rats [5][6]; the spinal cord injury work is in female mice [8]; the stress work is in male rats [9].
• The Alzheimer's-model work is described as animal-model work [1].
• Two of the sources are broad reviews rather than primary Semax studies [4][10].

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing here is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease — https://europepmc.org/article/PMC/PMC12755871
• [2] Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of a-beta by Metal Ion Stripping and Redox Silencing — https://europepmc.org/article/PMC/PMC12151629
• [3] Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study — https://europepmc.org/article/PMC/PMC13116926
• [4] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
• [5] Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage — https://europepmc.org/article/PMC/PMC12249733
• [6] ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke — https://europepmc.org/article/PMC/PMC11673339
• [7] The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons — https://pubmed.ncbi.nlm.nih.gov/41171324/
• [8] Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice — https://pubmed.ncbi.nlm.nih.gov/40692165/
• [9] Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress — https://pubmed.ncbi.nlm.nih.gov/39442746/
• [10] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — https://europepmc.org/article/PMC/PMC12753158